Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalil, N.
Right arrow Articles by Cheson, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalil, N.
Right arrow Articles by Cheson, B. D.
The Oncologist, Vol. 4, No. 5, 352-369, October 1999
© 1999 AlphaMed Press

Chronic Lymphocytic Leukemia

Nelson Kalila, Bruce D. Chesonb

a Medicine Branch and Cancer Therapy Evaluation Program (CTEP); b Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Executive Plaza North, Bethesda, Maryland, USA

Correspondence: Bruce D. Cheson, M.D., Head, Medicine Section, Clinical Investigation Branch, Cancer Therapy Evaluation Program, Executive Plaza North, Room 741, Bethesda, Maryland 20892, USA. Telephone 301-496-2522; Fax: 301-402-0557; e-mail: chesonb{at}ctep.nci.nih.gov

The diagnosis and management of chronic lymphocytic leukemia (CLL) is reviewed, including the basic aspects of epidemiology, molecular biology, and cytogenetics with clinical relevance. The importance of immunophenotype in the differential diagnosis of other lymphoproliferative disorders related to CLL, staging, prognostic factors, promising new drugs, and approaches is summarized.

Key Words. Chronic lymphocytic leukemia • CLL • CLL etiology • Biology • Cytogenetics • Diagnosis • Treatment • B-cell malignancies • Chronic lymphoproliferative disorders




This article has been cited by other articles:


Home page
 Anticancer ResHome page
J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER
Chronic Lymphocytic Leukaemia
Anticancer Res, February 1, 2009; 29(2): 605 - 615.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al.
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. T Wu
Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia
Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 133 - 140.
[Abstract] [PDF]

Home page
 BloodHome page
P. Chu, W. G. Wierda, and T. J. Kipps
CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes
Blood, June 15, 2000; 95(12): 3853 - 3858.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1999 by AlphaMed Press.
Advertisement